{"id":"albiglutide-weekly-injection","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"5%","effect":"Vomiting"},{"rate":"8%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2107841","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Albiglutide works by activating the glucagon-like peptide-1 (GLP-1) receptor, which helps to lower blood glucose levels.","oneSentence":"GLP-1 receptor agonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:35.545Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT02229227","phase":"PHASE3","title":"Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-21","conditions":"Diabetes Mellitus, Type 2","enrollment":814},{"nctId":"NCT02793154","phase":"PHASE4","title":"An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-09-26","conditions":"Diabetes Mellitus, Type 2","enrollment":4},{"nctId":"NCT02284009","phase":"PHASE2","title":"Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-10","conditions":"Diabetes Mellitus, Type 1","enrollment":67},{"nctId":"NCT02683746","phase":"PHASE3","title":"Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-16","conditions":"Diabetes Mellitus, Type 2","enrollment":308},{"nctId":"NCT02750930","phase":"PHASE4","title":"Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-10-07","conditions":"Diabetes Mellitus, Type 2","enrollment":8},{"nctId":"NCT02465515","phase":"PHASE4","title":"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-01","conditions":"Diabetes Mellitus","enrollment":9463},{"nctId":"NCT03015519","phase":"PHASE3","title":"A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-08-14","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT01077505","phase":"PHASE1","title":"An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-15","conditions":"Diabetes Mellitus, Type 2","enrollment":16},{"nctId":"NCT01147718","phase":"PHASE1","title":"A Drug Interaction Study of Albiglutide and Digoxin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-11","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT01406262","phase":"PHASE1","title":"Albiglutide Thorough ECG Study in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-06","conditions":"Diabetes Mellitus, Type 2","enrollment":94},{"nctId":"NCT01777282","phase":"PHASE3","title":"A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-23","conditions":"Diabetes Mellitus","enrollment":374},{"nctId":"NCT01098539","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":507},{"nctId":"NCT01128894","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":841},{"nctId":"NCT01098461","phase":"PHASE2","title":"Dose Ranging Study of Albiglutide in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Diabetes Mellitus, Type 2","enrollment":215},{"nctId":"NCT00838916","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":779},{"nctId":"NCT00849017","phase":"PHASE3","title":"Safety and Efficacy Study of Albiglutide in Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01","conditions":"Diabetes Mellitus, Type 2","enrollment":309},{"nctId":"NCT00849056","phase":"PHASE3","title":"Safety and Efficacy of Albiglutide in Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01","conditions":"Diabetes Mellitus, Type 2","enrollment":310},{"nctId":"NCT00839527","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":685},{"nctId":"NCT00518115","phase":"PHASE2","title":"Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Diabetes Mellitus, Type 2","enrollment":361},{"nctId":"NCT02229240","phase":"PHASE3","title":"Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-08","conditions":"Diabetes Mellitus, Type 2","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Albiglutide weekly injection","genericName":"Albiglutide weekly injection","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"GLP-1 receptor agonist Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}